Welcome to our dedicated page for Mainz Biomed NV SEC filings (Ticker: MYNZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mainz Biomed N.V. SEC filings document the issuer's molecular diagnostics business, governance actions, capital structure, and corporate transition reflected in later filings under Quantum Cyber N.V. and Nasdaq ticker QUCY. The record includes 8-K material-event reports, proxy materials for shareholder voting, and disclosures covering ordinary shares listed on the Nasdaq Capital Market.
The filings address material agreements, equity distribution arrangements, board appointments, name and ticker changes, Nasdaq listing-compliance matters, and capital-structure updates. They also include company disclosures tied to clinical or regulatory matters, operating and financial results, and risk and governance topics relevant to an emerging growth company.
Quantum Cyber N.V. terminated its at-the-market issuance sales agreement with Maxim Group LLC, effective June 7, 2026, under the agreement’s terms. This arrangement, originally dated October 1, 2025 and amended May 4, 2026, allowed the company to sell shares into the market over time.
Before ending the program, Quantum Cyber sold 3,280,927 Ordinary Shares for net cash proceeds of about $4,388,515. The company states it will not owe any termination penalties, so ending the agreement does not trigger extra costs.
Quantum Cyber N.V. is registering a shelf to offer up to $250,000,000 of securities. The shelf permits sales, from time to time, of ordinary shares, preferred shares, warrants, subscription rights and/or units in one or more offerings.
The prospectus states the company’s public float was $78,524,586, calculated using 22,767,254 ordinary shares outstanding and a referenced sale price of $3.56 per share as of May 21, 2026. The filing also discloses a Nasdaq last reported sale price of $2.45 per share as of June 2, 2026. The prospectus will be used with prospectus supplements that set specific terms, pricing and use of proceeds (general corporate purposes) for each takedown from the shelf.
Quantum Cyber N.V. entered into Amendment No. 1 to its Intellectual Property License Agreement with BP United Inc., changing how their collaboration is structured. Instead of an exclusive supply agreement, BP United will provide manufacturing and consulting services, while the Company keeps the previously agreed $5,000,000 cash payment to fund ramp-up of its own manufacturing for Licensed Products.
The Consideration Shares become issuable at execution of the amendment and vest in four equal installments on September 30, 2026, March 31, 2027, June 30, 2027, and September 30, 2027. The filing also furnishes, under Regulation FD, a June 2026 corporate slide deck outlining Quantum Cyber’s autonomous defense platform, large target markets, patent portfolio, capital-light public structure with 22 shares outstanding, no debt and no warrants, and plans for a vertically integrated, NDAA‑aligned US manufacturing complex and contract-ready platforms supported by letters of intent with General Cherry and SOCOM.
Quantum Cyber N.V. is asking shareholders to approve 11 proposals at its June 29, 2026 annual meeting in Amsterdam, with a record date of June 1, 2026. Items include ratifying Kreston Lentink as Dutch auditor for 2026, adopting Dutch statutory annual accounts for 2025 and granting directors discharge from liability for 2025 activities.
The Board also seeks to extend its authority to issue all unissued share capital and to limit or exclude pre-emption rights until June 28, 2031. Additional proposals would extend authorizations for repurchases of ordinary and preferred shares, approve past and future Board resolutions connected to new strategic initiatives, amend the articles to expand the corporate objects into quantum computing, next-generation cybersecurity and autonomous defense platforms, appoint Peter O’Rourke as director, and substantially amend the directors’ remuneration policy.
Quantum Cyber N.V. reports that it has regained compliance with Nasdaq’s minimum bid price requirement. Nasdaq’s Listing Qualifications Department confirmed that for 10 consecutive business days, from May 13, 2026 to May 27, 2026, the closing bid price of the company’s ordinary shares was at or above $1.00 per share.
As a result, the company now meets Nasdaq Listing Rule 5550(a)(2), and Nasdaq has closed the matter that began with a prior notice on March 20, 2026 regarding failure to maintain the minimum bid price.
Ben-Tzvi Avraham reported acquisition or exercise transactions in this Form 4 filing.
Quantum Cyber N.V. director Ben-Tzvi Avraham reported receiving a grant of 137,141 Ordinary Shares on May 8, 2026. The award was recorded at a price of $0.00 per share, indicating a non-cash share grant rather than a market purchase. Following this transaction, his directly held stake increased to 139,141 Ordinary Shares, reflecting a compensation-related equity award and not an open-market trade.
Quantum Cyber N.V. filed an extensive business update and reported that all remaining warrants were exercised, generating over $15 million in gross proceeds and leaving the company debt-free. Management plans to use the funds to expand research and development, build its commercialization team, and pursue strategic acquisitions for its autonomous defense and quantum-AI platforms.
The filing also details the company’s pivot from its prior diagnostics focus to an AI- and quantum-enabled autonomous systems business, including an IP license and commercial supply relationship with BP United Inc. Quantum Cyber highlights heavy reliance on defense and government customers, stringent export-control and AI/UAV regulations, and emerging quantum and counter‑UAS markets. Risk factors emphasize Nasdaq minimum bid-price non-compliance, substantial potential dilution from preferred shares convertible into hundreds of millions of ordinary shares, evolving AI and UAV regulation, cybersecurity threats, and the early, volatile state of quantum computing markets.
Quantum Cyber N.V. reported an intended sale of 200,000 shares by Guido Baechler via a Form 144 filing.
The filing also lists a 240,000-share stock award dated 04/22/2026 and a line showing 240,000 common shares with an associated value of $904,800.00 dated 05/22/2026.
Quantum Cyber N.V. director Peter O'Rourke has filed an initial Form 3 reporting his beneficial ownership in the company’s ordinary shares. The filing shows he beneficially owns no ordinary shares as of May 13, 2026, as confirmed by the footnote stating that no ordinary shares are beneficially owned.
NATAN DAVID reported acquisition or exercise transactions in this Form 4 filing.
Quantum Cyber N.V. director Natan David received a grant of ordinary shares as compensation. On May 8, 2026, he was awarded 137,141 ordinary shares at a stated price of $0.00 per share, bringing his directly held stake to 137,141 shares after the transaction.